Current Report Filing (8-k)
September 09 2022 - 04:16PM
Edgar (US Regulatory)
0000946644 false 0000946644 2022-09-09
2022-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
September 9, 2022
AIM IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-27072 |
|
52-0845822 |
(state
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
2117 SW Highway 484,
Ocala
FL |
|
34473 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
(352)
448-7797
AIM ImmunoTech Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
AIM |
|
NYSE American |
Item
7.01. Regulation FD Disclosure.
On
September 9, 2022, AIM ImmunoTech Inc. (the “Company”) posted a
company presentation to the “Events & Presentations”
subsection of the “Investor Relations” tab on the Company’s website
at https://AIMImmuno.com.
The
information in this item, including Exhibit 99.1, is “furnished”
and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section. It may only be incorporated by
reference in another filing under the Securities Exchange Act of
1934, as amended, or the Securities Act of 1933, as amended, if and
to the extent such subsequent filing specifically references the
information herein as being incorporated by reference in such
filing.
Cautionary
Statement
This
Current Report on Form 8-K, including Exhibit 99.1, contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such
as “may,” “will,” “expect,” “plan,” “anticipate” and similar
expressions (as well as other words or expressions referencing
future events or circumstances) are intended to identify
forward-looking statements. Many of these forward-looking
statements involve a number of risks and uncertainties. Among other
things, for those statements, we claim the protection of safe
harbor for forward-looking statements contained in the PSLRA. Any
forward-looking statements set forth in this presentation speak
only as of the date of this presentation. We do not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
September
9, 2022
|
AIM
IMMUNOTECH INC. |
|
|
|
By: |
/s/
Thomas K. Equels |
|
|
Thomas
K. Equels, CEO |
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Jan 2023 to Feb 2023
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Feb 2022 to Feb 2023